This function is mediated via the activation of the cAMP/PKA/CREB (cAMP-responsive element binding protein) and the transactivation of the EGF-R (epidermal growth factor receptor) leading to the activation of phosphatidylinositol-3 kinase (PI3K), protein kinase C(PKC), Akt-protein kinase B (AKT/PKB), extracellular regulated kinase (ERK1/2 or mitogen-activated protein kinase [MAPK]) signaling pathways and to the up-regulation of the expression of the cell cycle regulator cyclinD1 (Figure 3)
Increased Gastrointestinal Distress The most common side effect of GLP-1 medications is nausea
Our analysis demonstrated that the use of GLP-1 RAs was associated with a significantly decreased risk of all-cause mortality, MACEs, and MAKEs over a median follow-up period of 2.5 years
While more clinical trials are needed, these early findings suggest a potent role in hormonal resilience and circadian health restoration
lower abdomen, hips, and thighs go last
Do not use retatrutide if you have: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 History of pancreatitis Severe gastroparesis or other serious GI motility disorders Known hypersensitivity to any component of the drug Use with caution and close monitoring if you have: Existing cardiovascular disease, given the heart rate increase Gallbladder disease or a history of gallstones Kidney disease, as dehydration from GI side effects can worsen kidney function Type 1 diabetes or insulin-dependent Type 2 diabetes A history of eating disorders, as extreme appetite suppression can interact with disordered eating patterns in unpredictable ways Pregnancy is an absolute contraindication
